+

WO1995007924A1 - Compositions a base de ribozymes pour la modification des phenotypes cutanes associes au vieillissement de la peau et des cheveux et a d'autres de leurs etats - Google Patents

Compositions a base de ribozymes pour la modification des phenotypes cutanes associes au vieillissement de la peau et des cheveux et a d'autres de leurs etats Download PDF

Info

Publication number
WO1995007924A1
WO1995007924A1 PCT/US1994/010617 US9410617W WO9507924A1 WO 1995007924 A1 WO1995007924 A1 WO 1995007924A1 US 9410617 W US9410617 W US 9410617W WO 9507924 A1 WO9507924 A1 WO 9507924A1
Authority
WO
WIPO (PCT)
Prior art keywords
uga
ribozyme
gac
gag
gaa
Prior art date
Application number
PCT/US1994/010617
Other languages
English (en)
Inventor
Andy Shih
Jeffrey Michael Beckman
George T. Drivas
Mark G. Rush
Original Assignee
Andy Shih
Jeffrey Michael Beckman
Drivas George T
Rush Mark G
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Andy Shih, Jeffrey Michael Beckman, Drivas George T, Rush Mark G filed Critical Andy Shih
Publication of WO1995007924A1 publication Critical patent/WO1995007924A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y103/00—Oxidoreductases acting on the CH-CH group of donors (1.3)
    • C12Y103/01—Oxidoreductases acting on the CH-CH group of donors (1.3) with NAD+ or NADP+ as acceptor (1.3.1)
    • C12Y103/01022—3-Oxo-5alpha-steroid 4-dehydrogenase (NADP+) (1.3.1.22), i.e. cortisone alpha-reductase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y108/00—Oxidoreductases acting on sulfur groups as donors (1.8)
    • C12Y108/01—Oxidoreductases acting on sulfur groups as donors (1.8) with NAD+ or NADP+ as acceptor (1.8.1)
    • C12Y108/01007—Glutathione-disulfide reductase (1.8.1.7), i.e. glutathione reductase (NADPH)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/18—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with another compound as one donor, and incorporation of one atom of oxygen (1.14.18)
    • C12Y114/18001—Tyrosinase (1.14.18.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21037—Leukocyte elastase (3.4.21.37), i.e. neutrophil-elastase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/121—Hammerhead

Definitions

  • oligomers complementary oligonucleotides
  • This interaction can modify gene expression by interfering with the transcription or translation of the targeted DNA or RNA (antisense molecules) , and in the case of ribozymes, by cleaving the targeted sequence (Murray, J.A.H. and Crockett, N., 1992; Symons, R.H., 1991) .
  • Ribozy e technology combines the base pairing-specific targeting of the "antisense” approach with the ability of several different classes of RNA molecules to act like enzymes.
  • Ribozymes are RNA molecules which naturally cleave, or can be readily engineered to cleave, other RNA molecules (Symons, R.H., 1991) . Unlike antisense molecules which act stoichiometrically, ribozymes behave catalytically, like true enzymes, in that the ribozyme molecule is unchanged after cleaving its target RNA and can participate in additional cleavage reactions.
  • ribozymes there are at least five classes of ribozymes: 1) Plant viroid and satellite RNAs containing the so -called "hammerhead” motif; 2) RNase P or its RNA component; 3) Tecrahymena group I intron-like RNAs; 4) The "hairpin"-type motif of tobacco ringspot virus minus strand satellite RNA; and 5) The catalytic motifs of hepatitis delta virus.
  • RNase P ribozymes are normally self-cleaving (cis-cleaving) , and must be engineered to cleave other molecules (trans-cleaving) ' .
  • Such engineering involves the isolation of that subset of the entire sel -cleaving molecule's sequence which contains the enzymatic activity (the catalytic core) from that part of the molecule which contains the sequence(s) that are cleaved.
  • the smallest trans-cleaving ribozymes are the "hammerhead" class (Forster, A.C. and Symons, R.H., 1987; Uhlenbeck, O.C., 1987; Haseloff, J. and Gerlach, H.L., 1988) .
  • These ribozymes ranging from 25-50 nucleotides in length, consist of a catalytic core of about 11 nucleotides, with the remainder of the residues largely participating in the formation of 3 stem structures (see Figure 1) .
  • the ribozyme residues of stems I and III act as internal guide sequences (IGS) , hybridizing to the complementary target (substrate) RNA sequence.
  • a divalent cation usually Mg *'
  • cleavage of the substrate occurs immediately after the NUX trinucleotide, generating fragments with 5' hydroxyl and 2', 3' cyclic phosphate groups (reviewed by Symons, R.H., 1992) .
  • mice In mice (Agrawal, S. et al . , 1988; 1989a; 1989b; Sarin, P.S. et al., 1988; Stewart, R. et al., 1992; Zon, G., 1989) , and in humans (Hutcherson, S. . et al . , 1993) .
  • mice In mice (Agrawal, S. et al . , 1988; 1989a; 1989b; Sarin, P.S. et al., 1988; Stewart, R. et al., 1992; Zon, G., 1989)
  • humans Hutcherson, S. . et al . , 1993
  • nucleic acid-based pharmacological reagents While antisense approaches to viral cutaneous diseases are now in clinical trials, research involving nucleic acid-based pharmacological reagents has been primarily directed towards developing systemic therapeutics against pathologies such as leukemia, hepatitis, and AIDS. It is generally accepted that systemic delivery will require fairly large amounts of these therapeutics and raises concerns about cost and the possibility of eliciting an immune response.
  • the skin is the most accessible organ of the body, and nucleic acid-based therapeutics developed for the treatment of skin ailments can be applied topically and locally. This is advantageous because: 1) it allows relatively easy access to the cells one wishes to target; 2) it is likely to demonstrate far fewer complications than systemic administration; and 3) it should prove more cost effective, requiring much lower amounts than systemic dosages.
  • This invention concerns the production of oligonucleotides and their modified derivatives designed to reduce the levels of specific biological molecules present in the skin.
  • the oligomers are ribozymes.
  • the oligomers of the invention are used in inventive methods of treatment to counteract a variety of medically and cosmetically undesirable cutaneous conditions, such as intrinsic and actinic aging, psoriasis, alopecia, hirsutism, acne, and pigmentation, which are responsible for alterations in the functioning and appearance of the skin and related structures, and are due to aging, environmental insult, inflammation, or genetic predisposition.
  • the inventive methods disclosed here comprise contacting the skin of the patient with an effective amount of a composition comprising an oligomer and a suitable carrier such as liposome which inhibits the expression of a gene product associated with the cutaneous phenotype .
  • Stem 2 is formed by intramolecular base pairing within the ribozyme sequence.
  • Stems 1 and 3 are formed by the hybridization of guide sequences from the ribozyme, to complementary sequences found in the target substrate. The ribozyme is shown as a bold line and the target as a light line.
  • Interstitial Colla ⁇ enase mRNA-specific "Hammerhead” Ribozvme A "hammerhead” ribozyme (ICRZl) and target substrate (interstitial collagenase RNA) complex is shown.
  • the partial sequence of the substrate RNA is indicated by italics.
  • Ribozyme guide sequences conferring substrate specificity are indicated by bold letters.
  • the ribozyme cleavage site, at nucleotide position 955 Goldberg, G.I. et al., 1986), is indicated by an arro .
  • TC4RZ1 cleaves the substrate RNA at nucleotide position 83
  • TC4RZ2 cleaves at position 102
  • TC4RZ3 cleaves at position 223. All nucleotide positions reflect the numbering according to Drivas et al . (1990) but also include four additional nucleotides derived from the transcribed vector sequence.
  • ribozyme ribozyme
  • target substrate interleukin-6 RNA
  • Partial sequence of the substrate RNA is indicated by italics.
  • Ribozyme guide sequences conferring substrate specificity are indicated by bold letters.
  • the ribozyme cleavage site, at nucleotide position 510 is indicated by an arrow.
  • a "hammerhead” ribozyme (5ARRZ1) and target substrate (5- alpha-reductase RNA) complex is shown. Partial sequence of the substrate RNA is indicated by italics. Ribozyme guide sequences conferring substrate specificity are indicated by bold letters. The ribozyme cleavage site, at nucleotide position 656 (Andersson, S. et al . , 1991) , is indicated by an arrow.
  • the site of cleavage in a target molecule RNA is dependent on the selection of the ribozyme.
  • the substrate cleavage site is immediately 3 ' to the sequence NUX, where N is any nucleotide, X is any nucleotide except G, and U is uridine.
  • the length of complementary sequence between ribozvme and target will vary with each ribozyme system and the particular therapeutic setting or application.
  • each hybridizing arm (stems 1 and 3 in Figure 1) is generally 5-15 residues and results in base pairing to the substrate sequences immediately upstream and downstream of the UX sequence of the cleavage site. It is clear that several different types of ribozymes may be employed to achieve the specific cleavage of the targeted RNA molecules delineated here.
  • oligonucleotides are synthesized enzymatically by conventional techniques which are well known to those skilled in the art, or by using standard solid phase synthesis techniques using a commercially available machine such as an Applied Biosystems Incorporated, Model 392 DNA/RNA synthesizer. Oligonucleotides can also be synthesized by solution phase methods or recombinant DNA methods known to those skilled in the art .
  • the ribozyme oligonucleo ides of the invention may be conventional single-stranded RNA molecules or they may be partially or wholly modified by introducing: modifications of the backbone (e.g. mono- and dithio esters, methylphosphonates) ; modifications of the sugar moiety (e.g. deoxyribose, 2' alkyl groups, arabinose, alpha-anomers) ,- and modifications of the base (e.g. 2-aminopurine, inosine) using techniques and methods known to those skilled in the art. See for example: Usman, N. and Cedergren, R., 1992; Cook, P.D., 1991; Heidenreich, 0. et al . , 1993; Morvan, F.
  • modifications of the backbone e.g. mono- and dithio esters, methylphosphonates
  • modifications of the sugar moiety e.g. deoxyribose, 2' alkyl groups, arabinose, alpha-anomers
  • oligonucleotides may be further modified by the conjugation of chemical moieties either internally or terminally, such as: polycations (e.g. poly( ) lysine) ; hydrophobic groups (e.g. cholesterol) ; oligopeptides (e.g. Arg-Gly-Asp-Ser) ; or polypeptides (e.g antibodies) using techniques and methods known to those skilled in the art (see for example: ippert, B., 1992; Clarenc, J.P. et al . , 1993; Bunnell, B.A. et al .
  • polycations e.g. poly( ) lysine
  • hydrophobic groups e.g. cholesterol
  • oligopeptides e.g. Arg-Gly-Asp-Ser
  • polypeptides e.g antibodies
  • Ribozyme molecules have to reach the cell surface, cross the cell membrane, and act, either in the cytoplasm or the nucleus, on the target RNA.
  • the delivery of nucleic acid molecules to the skin is easier than to other tissues or organs in that the composition comprising the ribozyme is applied directly on a small exposed area.
  • a high concentration of the therapeutic can be administered with little systemic side effects .
  • a potential obstacle for the delivery of nucleic acid molecules to cutaneous targets is the stratum corneum (SC) .
  • SC stratum corneum
  • the stratum corneum is a matrix of keratinized cells, surrounded by lipids including cholesterol, free fatty acids and ceramides . These lipids form multilamellar arrays which impart resistance to percutaneous flux of polar compounds. However, the lamellar sheets are not conjoined and gaps between the sheets allow the passage of polar compounds to the lower epidermis and dermis . Similar openings also exist in the sheaths of hair follicles. In contrast, non-polar compounds, can easily diffuse through the SC because they readily partition in the lipid phase. These properties of the skin allow one to approach cutaneous delivery of nucleic acid molecules in two ways: Direct application of high concentrations, or by alteration of overall hydrophobicity. Each of these approaches may involve several specific protocols, such as those listed below:
  • enhancers as chey are generally known in the art (such as N-dodecyl di-isopranolamine and oleyl alcohol) to improve transport.
  • iontophoresis electrotransport
  • liposomes ro rarry nucleic acid molecules to targeted substrates.
  • the liposomal formulation can be either cationic, where the oligonucleotides bind to the exterior of the liposome, or conventional, where the nucleic acid molecules are entrapped within the vesicles. Both liposomal formulations will enhance the crossing of the SC barrier.
  • liposomes are readily taken up by cells (keratinocytes, melanocytes, fibroblasts, and cells of immune origin) within which they can release part or most of their therapeutic contents. Liposomes are widely used for delivery in cosmetic and topical applications, and applicable techniques and formulations are well known to those skilled in the art.
  • RNA or DNA vectors encoding ribozyme sequences Use of replicating or non-replicating RNA or DNA vectors encoding ribozyme sequences .
  • a large variety of such vectors are available or can be engineered using common molecular biological techniques well known to those skilled in the art.
  • the formulations of vehicles e.g. ointments, gels, creams
  • vehicles e.g. ointments, gels, creams
  • inventive oligonucleotides Some of the methods listed above can be found in: Zhu, N. et al., 1993; Juliano, R.L. and Akhtar, S., 1992; Chavany, C. et al . , 1992; L'Huillier, P.J. et ai . , 1992; Hsieh, S.Y. and Taylor, 1992; Citro, G. et al . , 1992; Ropert, C. et al . , 1992; Sioud, M.
  • the invention provides a number of ribozyme sequences, set forth in Table I below, designed to treat specific cutaneous conditions.
  • the names of the hammerhead ribozymes that are used in the accompanying examples are shown in column A.
  • the nucleotide sequences of the ribozymes are shown in column B.
  • the consensus catalytic core of the hammerhead ribozyme, 5' CUG-AUG- AGU-CCG-UGA-GGA-CGA-AA 3 ' is italicized and underlined in each ribozyme sequence.
  • the RNA targets against which specific ribozymes are designed are shown in column C. These targets and the cutaneous conditions they are associated with, are described more fully herein.
  • Column D lists the ribozyme cleavage site in the specified target RNA. Cleavage takes place 3' to the third nucleotide of the triplet listed. The location of the cleavage site in the target RNA is indicated by the number next to the third nucleotide and corresponds to the nucleotide position in the published sequence (see specific examples) .
  • Column E indicates the example number where the utilization of the specific ribozyme is described.
  • Intrinsic aging involves those alterations occurring in the skin of older individuals which has been protected from the sun. It is manifested cosmetically as fine wrinkling.
  • Actinic aging is the result of long-term exposure of skin to sunlight and is characterized by deep wrinkling, furrowing, and drying.
  • the majority of undesirable features associated with aging skin are the result of UV-induced photoaging (Uitto, J. et al., 1989b; Klingman, A.M., 1969) .
  • the histologic changes associated with photoaged skin have been demonstrated to be reversible (Gilhar, A. et al. , 1991) .
  • Treatments for aged skin essentially designed to reduce wrinkling, have included cosmetic plasty, chemical peels to promote collagen formation, and the implantation of silicone or collagen.
  • Pharmacological treatments have included anti- inflammatory agents such as hydrocortisone and, most recently, various natural and synthetic members of the vitamin A family, the retinoids (even though the latter may exhibit acute toxicities and complications of long-term usage) .
  • a major aspect of both intrinsic and actinic aging includes a decrease m the rate of keratinocyte, melanocyte, and fibroblast cell turnover.
  • Studies done on intrinsically aged skin fibroblasts and keratmocytes have demonstrated a marked decline in their growth potential and responsiveness to mitogens, as well as an increased responsiveness to growth inhibitors (Plinsko, A. and Gilchrest B.A., 1983; Stanulis-Praeger, B.M. and Gilchrest, B.A., 1986; Amoto, T.K. et al . , 1989) .
  • interferon-like molecule m the basal layer of the epidermis that can serve as a modulator inhibiting cellular proliferation
  • interferons have been shown to have a pronounced growth inhibitory effect on aged keratmocytes (Yaar, M. et ai, 1989; Peacoeke, M. et al . , 1989) .
  • proliferation inhibitors are good targets for intervention to reverse age related cutaneous symptoms .
  • Ribozyme molecules can be designed which will disrupt the synthesis of interferons alpha, beta, and gamma (Oliver, G. et al . , 1985; Fiers, W. et al., 1982; Nishi, T. et al . , 1985) .
  • Restoration of the proliferative and synthetic capacity of epidermal and dermal cells should reverse at least some of the cosmetic effects of aging.
  • tretinoin All-trans retinoic acid (tretinoin) has been shown to be effective in reversing many symptoms associated with actinic aging, both by inhibiting collagenase production and by stimulating collagen synthesis (Schwartz, E. et al . , 1991; Chen, S. et al., 1992; Kligman, L.H., 1989; Uitto, J. et al . , 1988b) .
  • Collagenase inhibition has other potential uses apart from the reversal of cutaneous aging. It can also be used in certain forms of arthritis where there is an increased degradation of collagen, and also in certain inherited disorders of collagen metabolism. In genetically inherited diseases such as dystrophic epidermolysis bullosa and Werner's syndrome, where the skin resembles that of aged individuals, elevated levels of
  • elastin The enzymes that degrade elastin (elastases) provide valuable targets for therapeutic intervention. Inhibition of these enzymes should result in an increase in functional elastin content thereby reversing some of the symptoms of intrinsic aging.
  • Ribozyme molecules can be used to reduce the synthesis of the principal elastases produced by fibroblasts and by polymorphonuclear leukocytes (see Table I and Examples 2 and 3) .
  • These therapeutics will have more than cosmetic value. They can also be used in several diseases where functional elastin fiber content is altered, such as emphysema. They might also find use in general connective tissue weakness of arteries where the drug can be applied by a systemic route.
  • ECM fibers--neutrophil collagenase Hasty, K.A. et al., 1990
  • type IV collagenase Wilhelm, S.M. et al . , 1989
  • stromelysins 1 and 2 Whitman, S.E. et al . , 1986; Muller, D. et al . , 1988
  • Inhibiting production of these enzymes with ribozymes should also prove beneficial for the repair of the ECM.
  • glycosaminoglycans and proteoglycans decrease with intrinsic ' aging (Johnston, K.J, et al . , 1985) . It is likely that an increased amount of glycosaminoglycans in the ECM, especially hyaluronic acid, will result in increased hydration and maintenance of turgor, giving aged skin a fuller and younger look. This can be achieved by ribozyme inhibition of the extracellular enzyme hyaluronidase, which is responsible for the breakdown of hyaluronic acid and other glycosaminoglycans (Bertolami, CN. and Donoff, R.B., 1982) .
  • ribozymes can also be used in any disorders where there is a decreased concentration of glycosaminoglycans, e.g. wound healing, where glycosaminoglycans have been shown to have a beneficial role. Since some glycosaminoglycans are degraded in fibroblasts, ribozyme molecules can also- be developed that will inhibit the synthesis of hyaluronic acid-binding proteins present on the
  • binding proteins include CD44 (Laurent, T.C. and Fraser J.R., 1992) .
  • the inhibition of its synthesis by ribozymes should result in an increase in the ECM concentration of hyaluronic acid (Table I and Example 6) .
  • These ribozymes may also be of therapeutic value in the control of tu origenesis and metastasis, where interactions of tumor cells with components of the ECM affect the migration of these cells.
  • Example 1 Ribozyme cleavage of a short sequence corresponding to a portion of the interstitial collagenase mRNA, a therapeutic target in the treatment of intrinsic and actinic cutaneous aging.
  • RNA polymerase promoter sequence A fragment of human interstitial collagenase antisense DNA (nucleotides 910-1009; Goldberg, G.I. et al . , 1986; GenBank accession #M13509) attached to the T7 RNA polymerase promoter sequence was synthesized on a ABI synthesizer. -P labeled RNA transcripts (100 nucleotides in length) , corresponding to a portion of human interstitial collagenase mRNA were generated essentially as described by Milligan et al . , (1987) , the content of which is hereby incorporated by reference in its entirety.
  • a labeled ribozyme ICRZl (sequence composition 5 ' -CUG-UCU-UUA-AAG- CUG-AUG-AGU-CCG-UGA-GGA-CGA-AAC-AUC-ACU-UC-3 ' , see Figure 2), designed to cleave after nucleotide 955, was also prepared according to Milligan et al .
  • the ribozyme and the substrate were mixed in a 1:2 molar ratio in a tmal volume of lOul containing 50mM Tris-HCl (pH 7.6! either m the presence or absence of 30mM MgCl 2 •
  • the reactions were incubated at 37 * C for 90 minutes, terminated with the addition of an equal volume of loading dye (0.25% bro ophenol blue, 0.25% xylene cyanol, 50% -formamide, and 30mM EDTA) , heated to 90 C for 2 minutes, resolved on a 15% 7M urea/p ⁇ lyacrylamide gel, and autoradiographed.
  • ICRZl ribozyme composition may be used to cleave collagenase mRNA both in vi tro and in vivo .
  • a therapeutically effective amount of this ribozyme composition (lOng to lmg) can be incorporated into a formulation consisting of a delivery vehicle or carrier such as cationic liposomes. This formulation may be applied directly to an affected area of the skin.
  • the ribozyme composition contained in this formulation may be used to cleave the collagenase mRNA present in skin cells and thus it may modify the expression of the target protein and may thereby mitigate the cutaneous condition.
  • Example 2 Ribozyme cleavage of a short sequence corresponding to a portion of the elastase/medullasin mRNA, a therapeutic target in the treatment of intrinsic cutaneous aging.
  • a fragment of human elastase/medullasin antisense DNA (nucleotides 242-322, Okano, K. et al . , 1989; GenBank accession #M34379) attached to the T7 RNA polymerase promoter sequence can be synthesized and -p labeled RNA transcripts (81 nucleotides in length) , corresponding to a portion of human elastase/medullasin mRNA may be generated.
  • Labeled ribozyme ELMRZl (sequence composition 5 ' -GCU-CCC-AGC-UGA-UGA-GUC-CGU-GAG-GAC-GAA-ACA-CCC-G- 3', see Table I) , designed to rieave after nucleotide 287, can also be prepared using a synthetic deoxyoligonucleotide template (5' CGG-GTG-TTT-CGT-CCT-CAC-GGA-CTC-ATC-AGC-TGG-GAG-CC-TAT-AGT- GAG-TCG-TAT-TA 3 ' ) and a short synthetic deoxyoligonucleotide- "18mer" (5' TAA-TAC-GAC-TCA-CTA-TAG 3 ' ) , according to the methods of Example 1.
  • a synthetic deoxyoligonucleotide template 5' CGG-GTG-TTT-CGT-CCT-CAC-GGA-
  • the ribozyme ELMRZ1 and the elastase/medullasin RNA substrate can be mixed in a 1:2 molar ratio, and incubated at 37 C for 90 minutes.
  • ribozyme and target substrate are incubated m the presence of 30mM Mg"
  • two cleavage products of the expected sizes of 35nts and 46nts should be produced.
  • the ELMRZ1 ribozyme composition may be used to cleave elastase/medullasin mRNA both in vi tro and in vivo .
  • a therapeutically effective amount of this ribozyme composition (lOng to l g) can be incorporated into a formulation consisting of a delivery vehicle or carrier such as cationic liposomes. This formulation may be applied directly to an affected area of the skin.
  • the ribozyme composition contained in this formulation may be used to cleave the elastase/medullasin mRNA present in skin cells and thus it may modify the expression of the target protein and may thereby mitigate the cutaneous condition.
  • Example 3 Ribozvme cleavage of a short sequence corresponding to a portion of the elastase 2 mRNA, a therapeutic target in the treatment of intrinsic cutaneous aging.
  • a fragment of human elastase 2 antisense DNA (nucleotides 282-362, Fletcher, T.S. et al . , 1987; GenBank accession #M16631) attached to the T7 RNA polymerase promoter sequence can be synthesized and '-P labeled RNA transcripts (81 nucleotides in length) , corresponding to a portion of human elastase 2 mRNA may be generated.
  • Labeled ribozyme EL2F.Z1 (sequence composition 5'- AUC-UUA-GAC-UGA-UGA-GUC-CGU-GAG-GAC-GAA-AAC-UGA-C-3' , see Table I) , designed to cleave after nucleotide 327, can also be prepared using a synthetic deoxyoligonucleotide template (5' GTC-AGT-TTT- CGT-CCT-CAC-GGA-CTC-ATC-AGT-CTA-AGA-TC-TAT-AGT-GAG-TCG-TAT-TA 3 ' ) and a short synthetic deoxyoligonucleotide-"18mer" (5' TAA-TAC- GAC-TCA-CTA-TAG 3') according to the methods of Example 1.
  • a synthetic deoxyoligonucleotide template 5' GTC-AGT-TTT- CGT-CCT-CAC-GGA-CTC-
  • the ribozyme EL2RZ1 and the elastase 2 RNA substrate can be mixed in a 1:2 molar ratio, and incubated at 37°C for 90 minutes.
  • ribozyme and target substrate are incubated in the presence of 30mM Mg " , two cleavage products of the expected sizes of 35nts and 46nts should be produced.
  • the EL2RZ1 ribozyme composition may be used to cleave elastase 2 mRNA both in vi tro and in vivo .
  • a therapeutically effective amount of this ribozyme composition (lOng to lmg) can be incorporated into a formulation consisting of a delivery vehicle or carrier such as cationic liposomes. This formulation may be applied directly to an affected area of the skin.
  • the ribozyme composition contained in this formulation may be used to cleave the elastase 2 mRNA present in skin cells and thus it may modify the expression of the target protein and may thereby mitigate the cutaneous condition.
  • Example 4 Ribozyme cleavage of a short sequence corresponding to a portion of the elastin mRNA, a therapeutic target in the treatment of actinic cutaneous aging.
  • a fragment of human elastin antisense DNA (nucleotides 241- 321, Fazio, M.J. et al . , 1988a; GenBank accession #M36860) attached to the T7 RNA polymerase promoter sequence can be synthesized and 32 P labeled RNA transcripts (81 nucleotides in length) , corresponding to a portion of human elastin mRNA may be generated.
  • Labeled ribozyme ELNRZ1 (sequence composition 5 ' -AAG- GCG-CCC-UGA-UGA-GUC-CGU-GAG-GAC-GAA-ACC-CUG-C-3 ' , see Table I), designed to cleave after nucleotide 286, can also be prepared using a synthetic deoxyoligonucleotide template (5' GCA-GGG-TTT- CGT-CCT-CAC-GGA-CTC-ATC-AGG-GCG-CCT-TC-TAT-AGT-GAG-TCG-TAT-TA 3 ' ) and a short synthetic deoxyoligonucleotide-"18mer" (5' TAA-TAC- GAC-TCA-CTA-TAG 3') using the methods of Example 1.
  • a synthetic deoxyoligonucleotide template 5' GCA-GGG-TTT- CGT-CCT-CAC-GGA-CTC-ATC-AG
  • the ribozyme ELNRZ1 and the elastin RNA substrate can be mixed in a 1:2 molar ratio, and incubated at 37'-C for 90 minutes.
  • ribozyme and cargec substrate are incubated in the presence of 30mM Mg " , two cleavage products of the expected sizes of 35nts and 46nts should be produced.
  • the ELNRZ1 ribozyme composition may be used to cleave elastin mRNA both in vi tro and in vi vo .
  • a therapeutically effective amount of this ribozyme composition (lOng to l g) can be incorporated into a formulation consisting of a delivery vehicle or carrier such as cationic liposomes . This formulation may be applied directly to an affected area of the skin.
  • the ribozyme composition contained in this formulation may be used to cleave the elastin mRNA present m skin cells and thus it may modify the expression of the target protein and may thereby mitigate the cutaneous condition.
  • Example 5 Ribozyme cleavage of a short sequence corresponding to a portion of the alpha-1- antitrypsin mRNA, a therapeutic target in the treatment of actinic cutaneous aging.
  • RNA transcripts (81 nucleotides in length) , corresponding to a portion of human alpha-1-antitrypsin mRNA may be generated.
  • Labeled ribozyme AATRZ1 sequence composition 5' -UGC-UGU-UGC-UGA-UGA-GUC-CGU-GAG-GAC-GAA-AUG-GUG-U-
  • nucleotide 244 designed to cleave after nucleotide 244, can also be prepared using a synthetic deoxyoligonucleotide template
  • l ⁇ mer (5' TAA-TAC-GAC-TCA-CTA-TAG 3') , according to the methods of Example 1.
  • the AATRZl ribozyme and the alpha-1-antitrypsin RNA substrate can be mixed in a 1:2 molar ratio, and incubated at 37 C for 90 minutes.
  • ribozyme and target substrate are incubated in the presence of 3OmM Mg " , two
  • the AATRZl ribozyme composition may be used to cleave alpha- 1-antitrypsin mRNA both in vi c and m vi vo .
  • a therapeutically effective amount of this ribozyme composition (lOng to lmg) can be incorporated into a formulation consisting of a delivery vehicle or carrier such as cationic liposomes. This formulation may be applied directly to an affected area of the skin.
  • the ribozyme composition contained m this formulation may be used to cleave the alpha-1-antitrypsm mRNA present m skin cells and thus it may modify the expression of the target protein and may thereby mitigate the cutaneous condition.
  • Example 6 Ribozyme cleavage of a short sequence corresponding to a portion of the CD44 mRNA, a therapeutic target in the treatment of intrinsic and actinic cutaneous aging.
  • Labeled ribozyme CDRZ1 (sequence composition 5 ' -GCU-GCA-CAC-UGA- UGA-GUC-CGU-GAG-GAC-GAA-AGG-AGU-U-3 ' , see Table I) , designed to cleave after nucleotide 316 will also be prepared using a synthetic deoxyoligonucleotide template (5' AAC-TCC-TTT-CGT-CCT- CAC-GGA-CTC-ATC-AGT-GTG-CAG-CC-TAT-AGT-GAG-TCG-TAT-TA 3') and a short synthetic deoxyoligonucleotide-"l ⁇ mer" (5' TAA-TAC-GAC-TCA- CTA-TAG 3 ' ) , according to the methods of Example 1.
  • a synthetic deoxyoligonucleotide template (5' AAC-TCC-TTT-CGT-CCT- CAC-GGA-C
  • the CDRZ1 ribozyme and the CD44 RNA substrate will be mixed m a 1:2 molar ratio, and be incubated at 37 C for 90 minutes.
  • ribozyme and target substrate are incubated in the presence of 30mM Mg"
  • two cleavage products of the expected size of 35nts and 46nts in length should be produced.
  • the CDRZ1 ribozyme composition may be used to cleave CD44 mRNA both m vi tro and m vi vo .
  • a therapeutically effective amount of this ribozyme composition (lOng to lmg * ) can be incorporated into a formulation consisting of a delivery vehicle or carrier such as cationic lipobomes. This formulation may be applied directly to an affected area of the skin.
  • the ribozyme composition contained in this formulation may be used to cleave the CD44 mRNA present in skin cells and thus it may modify the expression of the target protein and may thereby mitigate the cutaneous condition.
  • Psoriasis Psoriasis vulgaris is a chronic skin disorder affecting between 1% and 3% of the population. It is characterized by inflammation and by epidermal hyperproliferation. A number of therapeutic approaches are currently employed against psoriasis. Anti-proliferative agents are anthralin, methotrexate, and psoralens plus UVA radiation (320-400 nm) ("PUVA"); anti- inflammatory agents are cyclosporin, corticosteroids, and vitamin D, and agents whose functions are unclear are retinoids.
  • topical therapies such as anthralin and corticosteroids appear to be of only moderate success for limited psoriasis
  • systemic therapies such as retinoids and PUVA for more severe, recalcitrant psoriasis, where clinical responses are good, is complicated by toxicity. All of these drugs have associated complications (Ellis, CN. et al . , 1987; Stern, R.S. and Lange, R.J., 1988; Goldsmith, P. et al . , 1989) .
  • Human Ran/TC4 is a small nuclear GTP binding and hydrolyzing protein (GTPase) (Dasso, M. , 1993) which functions as part of a mitotic checkpoint control that prevents the onset of mitosis until the completion of DNA synthesis. The loss of Ran/TC4 results in a fatal premature initiation of mitosis.
  • GTPase GTP binding and hydrolyzing protein
  • the use of ribozymes to reduce Ran/TC4 expression ( Figure 4 and Example 7) may be of particular value for enhancing the efficacy and greatly reducing the toxicity of currently used therapeutics, such as methotrexate.
  • EGF Epidermal Growth Factor
  • TGF Tumor Necrosis Factor
  • hyperproliferative diseases including psoriasis are characterized by the overexpression and altered distribution of EGF receptors and TGF-alpha (Elder, J.T. et al . , 1989; Watts, P. et al., 1990; Detmar, M. et al . , 1992) . In psoriasis they contribute in an autocrine fashion to the hyperproliferation of keratinocytes (Watts, J. et al . , 1992) .
  • TNF-alpha has also been found in increased levels in psoriatic lesions relative to those of normal skin, and mRNA and protein levels of this cytokine were significantly decreased in peripheral blood mononuclear cells of psoriatic patients after PUVA therapy (Neuner, P. et al . , 1992) . It appears that this cytokine can upregulate TGF-alpha and growth factor receptors, triggering cellular hyperproliferation. Ribozyme molecules can be designed which will disrupt the synthesis of EGF receptors (Ullrich, A. et al . , 1984) , TGF-alpha (Table I and Example 8) and TNF-alpha (Table I and Example 9) .
  • Interleukin (ID -6.
  • IL-6 is thus an attractive target for intervention.
  • Ribozyme molecules designed against IL-6 mRNA should lower IL-6 levels (see Figure 6 and Example 10) .
  • Such anti-IL-6 therapeutics will have uses beyond the treatment of psoriasis, since IL-6 has also been implicated in the manifestations of many immune response diseases and bacterial infections .
  • Interleukin (IL)-l and IL-8 Interleukin (IL)-l and IL-8.
  • IL-8 was consistently found to be elevated in tissue extracts of lesional psoriatic skin, compared to the umnvolved skin of the same patient (Takematsu, H. and Tagami, H., 1993) .
  • Supernatants from lesional psoriatic cell culture potentiated the acute activation of T-lymphocytes, a step apparently critical for the maintenance of the lesions (Chang, E.Y. et al . , 1992) . This potentiation was directly correlated with the severity of the lesion.
  • Anti-IL-1 and IL-8 antibodies partly blocked the potentiation, suggesting that IL-1 and IL-8 are partly responsible for lesion maintenance.
  • IL-1 and IL-8 levels have been shown to decrease in patients receiving PUVA therapy (Neuner, P. et al . , 1992) .
  • this finding indicates the amenability of IL-1 and IL-8 to down regulation by ribozymes (see Table I and Examples 11, 12, and 13) .
  • ICM Intercellular Adhesion Molecule
  • ICAM-1 Intercellular Adhesion Molecule (ICAM)-l expression has been shown to increase in many skin conditions including psoriasis. ICAM-1 is believed to play an important role in the recruitment of circulating leukocytes to the skin. Interestingly, PUVA, which has been shown to be partially effective in the treatment of psoriasis, reduces the level of ICAM-1 mRNA in keratinocytes (Krutmann, J. et al . , 1991) . A specific reduction of ICAM-1 levels could be achieved by design of specific ribozymes (Table I and Example 14) directed
  • Ribozyme therapeutics should prove highly useful in muting the undesirable effects of all of the above mentioned factors and many, if not all, of the complications associated with the pharmacologically pluripotent drugs currently used for psoriatic disease management can also be avoided.
  • Example 7 Ribozyme cleavage of Ran/TC4 RNA, a therapeutic target in the treatment of Psoriasis.
  • a 944 base pair fragment of human Ran/TC4 cDNA including the entire open reading frame (Drivas, G.T. et al . , 1990, GenBank accession # M31469) , was cloned into vector pGEM3Z.
  • the plasmid was linearized with restriction endonuclease Pstl and 3 -P (alpha- 32 p ATp (NEN) ) -labelled RNA transcripts were generated using T7 RNA polymerase essentially as described by Milligan et al . , (1987) .
  • the transcripts were separated and purified on a 4% 7M urea/polyacrylamide gel, localized by autoradiography and eluted from gel slices using a standard procedure (Sambrook, J. et al . , 1989) .
  • Ran/TC4-specific "hammerhead" ribozymes (sequence compositions : TC4RZ1, 5 ' -CCA-ACC-AAC-UGA-UGA-GUC-CGU-GAG-GAC-GAA- ACA-AGU-U-3 ' , TC4RZ2, 5 ' -UUU-UCC-AGC-UGA-UGA-GUC-CGU-GAG-GAC-GAA- ACC-ACC-A-3 ' , TC4RZ3, 5 ' -AUA-CAU- ⁇ JGC-UGA-UGA-GUC-CGU-GAG-GAC-GAA- ACU-UAA-U-3 ' , see Figure 4) were also prepared according to Milligan et al .
  • T4RZ1 5' AAC-TTG-TTT-CGT-CCT-CAC-GGA-CTC-ATC-AGT- TGG-TTG-GCT-ATA-GTG-AGT-CGT-ATT- 3 '
  • TC4RZ2 5 ' TGG-TGG-TTT-CGT- CCT-CAC-GGA-CTC-ATC-AGC-TGG-AAA-ACT-ATA-GTG-AGT-CGT-ATT-A 3 '
  • TC4RZ3 5 ' ATT-AAG-TTT-CGT-CCT-CAC-GGA-CTC-ATC-AGC-AAT-GTA-TCT- ATA-GTG-AGT-CGT-ATT-A 3 '
  • a short synthetic DNA oligonucleotide- "18mer"- that hybridizes to the template and generates a T7
  • each ribozyme and the Ran/TC4 RNA substrate were mixed in a 1:2 molar ratio in a final volume of lOul containing 50mM Tris-HCl (pH 7.6) either in the presence or absence of 30mM MgCl .
  • the reactions were incubated at 37 : C for 90 minutes, terminated by the addition of an equal volume of loading dye (0.25% bromophenol blue, 0.25% xylene cyanol, 50% formamide, and 30mM EDTA) , heated to 90 C for 2 minutes, resolved on a 4% 7M urea/polyacrylamide gel, and autoradiographed.
  • loading dye 0.25% bromophenol blue, 0.25% xylene cyanol, 50% formamide, and 30mM EDTA
  • ribozyme compositions (TC4RZ1, TC4RZ2, and TC4RZ3 ) , they may be used to cleave Ran/TC4 mRNA both in vi tro and in vi vo .
  • a therapeutically effective amount of these ribozyme compositions (lOng to lmg) can be incorporated into a formulation consisting of a delivery vehicle or carrier such as cationic liposomes. These formulations may be applied directly to an affected area of the skin.
  • the ribozyme composition contained in this formulation may be used to cleave the Ran/TC4 mRNA present in skin cells and thus it may modify the expression of the target protein and may thereby mitigate the cutaneous condition.
  • Example 8 Ribozyme cleavage of a short sequence corresponding to a portion of the TGF-alpha mRNA, a therapeutic target in the treatment of psoriasis .
  • a fragment of human TGF-alpha antisense DNA (nucleotides 174-254, Jakowlew, S.B. et al . , 1988; GenBank accession M31172) attached to the T7 RNA polymerase promoter sequence can be synthesized and --P labeled RNA transcripts (81 nucleotides in length) , corresponding to a portion of human TGF-alpha mRNA may be -generated.
  • Labeled ribozyme TGFRZ1 (sequence composition 5'- GCA-CCA-AAC-UGA-UGA-GUC-CGU-JA -GAC-GAA-ACU-GCA-G-3 ' , see Table I) , designed to cleave after nucleotide 219, can also be prepared using a synthetic deoxyoligonucleotide template (5' CTG-CAG-TTT- CGT-CCT-CAC-GGA-CTC-ATC-AGT-TTG-GTG-CC-TAT-AGT-GAG-TCG-TAT-TA 3 ' ) and a short synthetic deoxyoligonucleotide-"l ⁇ mer" (5' TAA-TAC- GAC-TCA-CTA-TAG 3'), using the methods of Example 1.
  • a synthetic deoxyoligonucleotide template 5' CTG-CAG-TTT- CGT-CCT-CAC-GGA-CTC-A
  • the TGFRZl ribozyme and the TGF-alpha RNA substrate can be mixed in a 1:2 molar ratio, and can be incubated at 37°C for 90 minutes.
  • ribozyme and target substrate are incubated in the presence of 3OmM Mg"
  • two cleavage products of the expected sizes of 35nts and 46nts should be produced.
  • the TGFRZl ribozyme composition may be used to cleave TGF- alpha mRNA both in vi tro and in vi vo .
  • a therapeutically effective amount of this ribozyme composition (lOng to lmg) can be incorporated into a formulation consisting of a delivery vehicle or carrier such as cationic liposomes. This formulation may be applied directly to an affected area of the skin.
  • the ribozyme composition contained in this formulation may be used to cleave the TGF-alpha mRNA present m skin cells and thus it may modify the expression of the target protein and may thereby mitigate the cutaneous condition.
  • Example 9 Ribozyme cleavage of a short sequence corresponding to a portion of the TNF-alpha mRNA, a therapeutic target in the treatment of psoriasis.
  • a fragment of human TNF-alpha antisense DMA (nucleotides 1584-1664, Marmenout, A. et al . , 1985; GenBank accession -*M26331) attached to the T7 RNA polymerase promoter sequence can be synthesized and '-P labeled RNA transcripts (81 nucleotides in length) , corresponding to a portion of human TNF-alpha mRNA may be generated.
  • Labeled ribozyme TMFRZl (sequence composition 5'- ACA-UGG-GCC-UGA-UGA-GUC-CGU-GAG-GAC-GAA-AAG-GCU-U-3' , see Table I), designed to cleave after nucleotide 1629, can also be prepared using a synthetic deoxyoligonucleotide template (5' AAG- CCT- TTT-CGT-CCT-CAC-GGA-CTC-AT -AGG-CCC-ATG-TC-TAT-AGT-GAG-TCG- TAT-TA 3') and a short synthetic deoxyoligonucleotide-"18mer" (5' TAA-TAC-GAC-TCA-CTA-TAG 3 ' ) , according to the methods of Example 1.
  • a synthetic deoxyoligonucleotide template 5' AAG- CCT- TTT-CGT-CCT-CAC-GGA-CTC-AT
  • the TMFRZl ribozyme and the TNF-alpha RNA substrate can be mixed m a 1:2 molar ratio, and incubated at 37"C for 90 minutes.
  • ribozyme and target substrate are incubated in the presence of 30mM Mg"
  • two cleavage products of the expected sizes of 35nts and 46nts should be produced.
  • the TNFRZ1 ribozyme composition may be used to cleave TNF- alpha mRNA both in vi tro and in vivo .
  • a therapeutically effective amount of this ribozyme composition (lOng to lmg) can be incorporated into a formulation consisting of a delivery vehicle or carrier such as cationic liposomes. This formulation may be applied directly to an affected area of the skin.
  • the ribozyme composition contained in this formulation may be used to cleave the TNF-alpha mRNA present in skin cells and thus it may modify the expression of the target protein and may thereby mitigate the cutaneous condition.
  • Example 10 Ribozyme cleavage of a short sequence corresponding to a portion of the interleukin-6 mRNA, a therapeutic target in the treatment of psoriasis .
  • RNA transcripts (81 nucleotides in length) , corresponding to a portion of human interleukin-6 mRNA were generated.
  • Labeled ribozyme IL6RZ1 (sequence composition 5'- GAA-CUG-GAU-CAG-CUG-AUG-AGU-CCG-UGA-GGA-CGA-AAC-UUU-GUA-C-3 ' , see Figure 6) , designed to cleave after nucleotide 510, was also prepared using a synthetic deoxyoligonucleotide template (5' GTA- CAA-AAG-TTT-CGT-CCT-CAC-GGA-CTC-ATC-AGC-TGA-TCC-AGT-TCC-TAT-AGT- GAG-TCG-TAT-TA 3 ' ) and a short synthetic deoxyoligonucleotide- "18mer" (5' TAA-TAC-GAC-TCA-CTA-TAG 3') , using the methods of Example 1.
  • the IL6RZ1 ribozyme and the IL6 RNA substrate were mixed in a 1:2 molar ratio in the presence or absence of 30mM MgCl_ .
  • the reactions were incubated at 37-C for 90 minutes.
  • the ribozyme and target substrate were incubated m the presence of 30mM Mg
  • two cleavage products of the expected sizes of 35nts and 46nts were produced.
  • it may be used to cleave IL-6 mRNA both m vi tro and m vi vo .
  • a therapeutically effective amount of this ribozyme composition (lOng to lmg) can be incorporated into a formulation consisting of a delivery vehicle or carrier such as cationic liposomes. This formulation may be applied directly to an affected area of the skin.
  • the ribozyme composition contained in this formulation may be used to cleave the IL-6 mRNA present in skin cells and thus it may modify the expression of the target protein and may thereby mitigate the cutaneous condition.
  • Example 11 Ribozyme cleavage of a short sequence corresponding to a portion of the IL-1-alpha mRNA, a therapeutic target in the treatment of psoriasis .
  • a fragment of human IL-1- alpha antisense DNA (nucleotides 182-262, Nishida, T. et al . , 1987; GenBank accession M15329) attached to the T7 RNA polymerase promoter sequence can be synthesized and -P labeled RNA transcripts (81 nucleotides in length) , corresponding to a portion of human IL-1-alpha mRNA may be generated.
  • Labeled ribozyme IL1ARZ1 (sequence composition 5'- UUG-GUU-GCC-UGA-UGA-GUC-CGU-GAG-GAC-GAA-AUA-CCA-C-3 ' , see Table I) , designed to cleave after nucleotide 227, can also be prepared using a synthetic deoxyoligonucleotide template (5' GTG-GTA-TTT- CGT-CCT-CAC-GGA-CTC-ATC-AGG-CAA-CCA-AC-TAT-AGT-GAG-TCG-TAT-TA 3 ' ) and a short synthetic deoxyoligonucleotide-"18mer" (5' TAA-TAC- GAC-TCA-CTA-TAG 3') , according to the methods of Example 1.
  • a synthetic deoxyoligonucleotide template 5' GTG-GTA-TTT- CGT-CCT-CAC-GGA-C
  • the IL1ARZ1 ribozyme and the IL-1-alpha RNA substrate can be mixed in a 1:2 molar ratio, and incubated at 37°C for 90 minutes.
  • ribozyme and target substrate are incubated in the presence of 3OmM Mg , two cleavage products of the expected sizes of 35nt and 45nts should be produced.
  • the IL1ARZ1 ribozyme composition may be used to cleave IL-1- alpha mRNA both m vi tro and m vi vo .
  • a therapeutically effective amount of this ribozyme composition (lOng to lmg) can be incorporated into a formulation consisting of a delivery vehicle or carrier such as cationic liposomes. This formulation may be applied directly to an affected area of the skin.
  • the ribozyme composition contained m this formulation may be used to cleave the IL-1-alpha mRNA present in skin cells and thus it may modify the expression of the target protein and may thereby mitigate the cutaneous condition.
  • Example 12 Ribozyme cleavage of a short sequence corresponding to a portion of the IL-1-beta mRNA, a therapeutic target in the treatment of psoriasis.
  • a fragment of human IL-1-beta antisense DNA (nucleotides 238-318, Nishida, T. et al . , 1987; GenBank accession 4M15330) attached to the T7 RNA polymerase promoter sequence can be synthesized and -P labeled RNA transcripts (81 nucleotides m length) , corresponding to a portion of human IL-1-beta mRNA may be generated.
  • Labeled ribozyme IL1BRZ1 (sequence composition 5'- CAA-CAA-CUC-UGA-UGA-GUC-CGU-GAG-GAC-GAA-AGC-GGC-C-3 ' , see Table I) , designed to cleave after nucleotide 283, can also be prepared using a synthetic deoxyoligonucleotide template (5' GGC-CGC-TTT- CGT-CCT-CAC-GGA-CTC-ATC-AGA-GTT-GTT-GC-TAT-AGT-GAG-TCG-TAT-TA 3 ' ) and a short synthetic deoxyoligonucleotide-"18mer" (5' TAA-TAC- GAC-TCA-CTA-TAG 3' ) , using the methods of Example 1.
  • a synthetic deoxyoligonucleotide template 5' GGC-CGC-TTT- CGT-CCT-CAC-GGA-CTC
  • the IL1BRZ1 ribozyme and the IL-1-beta RNA substrate can be mixed in a 1:2 molar ratio, and incubated at 37 C for 90 minutes.
  • ribozyme and target substrate are incubated m the presence of 30mM Mg"
  • two cleavage products of the expected sizes of 35nts and 46nts should be produced.
  • the IL1BRZ1 ribozyme composition may be used to cleave IL-1- beta mRNA both m vi tro and m vi vo .
  • a therapeutically effective amount of this ribozyme composition (lOng to lmg) can be incorporated into a formulation consisting of a delivery vehicle or carrier such as cationic liposomes. This formulation may be applied directly to an affected area of the skin.
  • the ribozyme composition contained in this tormulation may be used to cleave the IL-1-beta mRNA present m skin cells and thus it may modify the expression of the target protein and may thereby mitigate the cutaneous condition.
  • Example 13 Ribozyme cleavage of a short sequence corresponding to a portion of the IL-8 mRNA, a therapeutic target in the treatment of psoriasis.
  • a fragment of human IL-8 antisense DNA (nucleotides 1565- 1645, Mukaida., N. et al . , 1989; GenBank accession #M28130) attached to the T7 RNA polymerase promoter sequence can be synthesized and 3: P labeled RNA transcripts (81 nucleotides in length) , corresponding to a portion of human IL-8 mRNA may be generated.
  • Labeled ribozyme IL8RZ1 (sequence composition 5 ' -GCU- GCC-AAC-UGA-UGA-GUC-CGU-GAG-GAC-GAA-AAG-CCA-C-3 ' , see Table I), designed to cleave after nucleotide 1610, can also be prepared using a synthetic deoxyoligonucleotide template (5' GTG-GCT-TTT- CGT-CCT-CAC-GGA-CTC-ATC-AGT-TGG-CAG-CC-TAT-AGT-GAG-TCG-TAT-TA 3 ' ) and a short synthetic deoxyoligonucleotide-"18mer" (5' TAA-TAC- GAC-TCA-CTA-TAG 3') , according to the methods of Example 1.
  • a synthetic deoxyoligonucleotide template 5' GTG-GCT-TTT- CGT-CCT-CAC-GGA-C
  • the IL8RZ1 ribozyme and the IL-8 RNA substrate can be mixed in a 1:2 molar ratio, and incubated at 37°C for 90 minutes.
  • ribozyme and target substrate are incubated in the presence of 30mM Mg " , two cleavage products of the expected sizes of 35nts and 46nts should be produced.
  • the IL8RZ1 ribozyme composition may be used to cleave IL-8 mRNA both in vi tro and in vivo .
  • a therapeutically effective amount of this ribozyme composition (lOng to lmg) can be incorporated into a formulation consisting of a delivery vehicle or carrier such as cationic liposomes. This formulation may be applied directly to an affected area of the skin.
  • the ribozyme composition contained m this formulation may be used to cleave the IL-8 mRNA present in skin cells and thus it may modify the expression of the target protein and may thereby mitigate the cutaneous condition.
  • Example 14 Ribozyme cleavage of a short sequence corresponding to a portion of the ICAM-1 mRNA, a therapeutic target in the treatment of psoriasis.
  • a fragment of human ICAM-1 antisense DNA (nucleotides 173- 253, Simmons, D. et al . , 1988; GenBank accession #X06990) attached to the T7 RNA polymerase promoter sequence can be synthesized and '-P labeled RNA transcripts (81 nucleotides in length) , corresponding to a portion of human ICAM-1 mRNA may be generated.
  • Labeled ribozyme ICMRZ1 (sequence composition 5 ' -GCA- GGA-GCC-UGA-UGA-GUC-CGU-GAG-GAC-GAA-AUC-CUU-U-3' , see Table I), designed to cleave after nucleotide 218, can also be prepared using a synthetic deoxyoligonucleotide template (5' AAA-GGA-TTT- CGT-CCT-CAC-GGA-CTC-ATC-AGG-CTC-CTG-CC-TAT-AGT-GAG-TCG-TAT-TA 3 ' ) and a short synthetic deoxyoligonucleotide-"18mer" (5' TAA-TAC- GAC-TCA-CTA-TAG 3' ) , using the methods of Example 1.
  • a synthetic deoxyoligonucleotide template 5' AAA-GGA-TTT- CGT-CCT-CAC-GGA-CTC-ATC-
  • the ICMRZ1 ribozyme and the ICAM-1 RNA substrate can be mixed in a 1:2 molar ratio, and incubated at 37 J C for 90 minutes.
  • ribozyme and target substrate are incubated in the presence of 30mM Mg"
  • two cleavage products of the expected sizes of 35nts and 46nts should be produced.
  • the ICMRZl ribozyme composition may be used to cleave ICAM-1 mRNA both in vi tro and m vivo .
  • a therapeutically effective amount of this ribozyme composition (lOng to lmg) can be incorporated into a formulation consisting of a delivery vehicle or carrier such as cationic liposomes. This formulation may be applied directly to an affected area of the skin.
  • the ribozyme composition contained in this formulation may be used to cleave the ICAM-1 mRNA present in skin cells and thus it may modify the expression of the target protein and may thereby mitigate the cutaneous condition.
  • Androgens are the primary regulators of hair growth.
  • Testosterone is converted to 5-alpha-dihydrotestosterone (5- alpha-DHT) by the enzyme 5-alpha-reductase (5-alpha-R) .
  • 5-alpha-DHT 5-alpha-dihydrotestosterone
  • 5-alpha-R 5-alpha-reductase
  • Both testosterone and 5-alpha-DHT can bind to androgen receptors (Mainnaring, W.I. P., 1987) , but the latter is thought to play a more important growth regulatory role in hair follicles (Imperato-McGinley, J. et al . , 1984) .
  • Two closely related isozymes of 5-alpha-R, 5-alpha-Rl and 5-alpha-R2 have been cloned (Andersson, S. and Russel, D.W., 1990; Andersson, S. et al. , 1991)
  • 5- alpha-R activity is greater in follicles from the balding scalp compared with non-balding areas (Sweikert, H.U. and Wilson, J.D., 1972) .
  • ribozymes would also be useful in preventing hirsutism (e.g. unwanted facial hair growth m males and females) . Since 5-alpha-DHT seems to increase racial hair growth, topical ribozyme inactivation of 5-alpha-R should reduce hirsutism.
  • Acne vulgaris an inflammatory condition of the pilosebaceous units of the face and trunk, is a disease whose clinical manifestations can range from minor comedones to disfiguring nodules and cysts.
  • the pathogenesis of acne involves a complex interplay of at least four etiological factors: 1) increased sebum production by the sebaceous glands, in response to androgens; 2) ductal hypercornification, leading to obstruction; 3) increased colonization of the duct by ropioni-bacterium acnes ; and 4 ) inflammation triggered in part, by P. acnes products.
  • Present therapeutic modalities include agents to normalize keratinization, decrease sebaceous gland activity, decrease the P. acnes population, and reduce inflammation.
  • Common drugs include retinoids, antibiotics, and steroids. Of these, the retinoids have perhaps the greatest beneficial effects by influencing the four interrelated pathogenic factors of acne.
  • the efficacy of antibiotics is being challenged as the incidence of antibiotic resistant P. acnes , and in particular multiply resistant strains increases.
  • one of the primary comedolytic agents used for self-treatment benzoyl peroxide, has been demonstrated to enhance the development of carcinomas from papillomas in mice, which raises concerns for its chronic usage.
  • Androgen stimulation is a prerequisite for acne (reviewed in Acne, by W.J. Cunliffe, 1989) . Androgens stimulate the sebaceous gland directly, resulting in an increase in gland size and sebum excretion rate. Sebum excretion is significantly higher in acne patients and this increase is related to the severity of the disease.
  • the androgens testosterone and 5-alpha dihydrotestosterone (DHT) have the most potent effect on sebum production, with DHT being 2-3 times more active than testosterone. This suggests that modulation of the levels of the 5oc-reductase enzyme or the DHT receptor within these target cells will result in a significant reduction of sebum production.
  • DHT 5-alpha dihydrotestosterone
  • Example 15 Ribozvme cleavage of a short sequence corresponding to a portion of the 5-alpha reductase II mRNA, a therapeutic target in the treatment of alopecia, hirsutism, and acne.
  • a labeled ribozyme 5ARRZ1 (sequence composition 5 ' -AGU-GCU-GGG-AGG-CUG-AUG-AGU-CCG-UGA-GGA- CGA-AAC-CAA-GUG-GC-3 ' , see Figure 8) , designed to cleave after nucleotide 656, was also prepared using a synthetic deoxyoligonucleotide template (5' GCC-ACT-TGG-TTT-CGT-CCT-CAC- GGA-CTC-ATC-AGC-CTC-CCA-GCA-CTC-TAT-AGT-GAG-TCG-TAT-TA 3 ' ) and a short synthetic deoxyol ⁇ gonucleotide-"18mer" (5' TAA-TAC-GAC- TCA-CTA-TAG 3') , according to the methods of Example 1.
  • Both ribozyme and substrate were separated and purified.
  • the 5ARRZ1 ribozyme and 5-alpha reductase II RNA substrate were mixed m a 1:2 molar ratio in the presence or absence of 30mM MgCl .
  • the reactions were incubated at 37-C for 90 minutes.
  • Figure c when the ribozyme and target substrate were incubated in the presence of 3OmM Mg", two cleavage products of the expected sizes of 32nts and 50nts were produced.
  • this ribozyme composition may be used to cleave 5-alpha reductase II mRNA both in vi tro and in iv .
  • a therapeutically effective amount of this ribozyme composition (lOng to lmg) can be incorporated into a formulation consisting of a delivery vehicle or carrier such as cationic liposomes. This formulation may be applied directly to an affected area of the skin.
  • the ribozyme composition contained m this formulation may be used to cleave the 5-alpha reductase II mRNA present in skin cells and thus it may modify the expression of the target protein and may thereby mitigate the cutaneous condition.
  • the amount of melanin in the epidermis is regulated both by its production within melanocytes and its degradation within keratinocytes.
  • Tyrosinase is the key enzyme in the biosynthesis of melanin, although additional enzymatic activities that modify the quantity or quality of melanin have been identified, including: a dopachrome tautomerase, a peroxidase, and a gamma- glutamyl transpeptidase. Some of these activities are believed to be products of the brown and sla ty loci, which encode proteins that share many features with tyrosinase (Kwon, B.S. et al . , 1987a; Jimenez, M. et al .
  • Ribozyme molecules can be designed to effectively decrease the synthesis of these proteins by melanocytes.
  • These reagents could be used for the treatment of hyperpigmentation conditions such as melasma, freckling, old age spots, and lentigo. Current treatment for these conditions is the application of 2-4% hydroquinone, which is generally safe, but often has a less than satisfactory effect (Engasser, P.G. and Maribach, H.I. , 1981) .
  • dopaquinone the product of the tyrosinase reaction
  • dopaquinone is converted to cysdopas (condensation products of quinone and sulhydryl compounds) , and subsequently into pheomelanins-- (yellow to reddish brown pigments) rather than the darker eumelanins .
  • cysdopas condensation products of quinone and sulhydryl compounds
  • pheomelanins-- yellow to reddish brown pigments
  • cysteine Two types of thiols, glutathione (GSH* and cysteine, are involved in the formation of cysdopas. Therefore, enzymes which influence the redox state of the glutathione system (e.g. GSH reductase) can affect the level of melanization (Prota, G., 1980,-1993) .
  • GSH reductase Reduction of GSH levels in melanocytes could be achieved by use of ribozymes designed to inhibit the synthesis of GSH reductase (Table I and Example 17) .
  • the inhibition of GSH reductase should result in the increased production of the darker eumelanin type pigments as a result of the "shunting" of dopaquinone into this biosynthetic pathway. This should lead to a "darkening" or tanning effect of the areas of the hair or skin to which these reagents have been applied.
  • Example 16 Ribozyme cleavage of a short sequence corresponding to a portion of the tyrosinase mRNA, a target in the alteration of pigmentation.
  • a fragment of human tyrosinase antisense DNA (nucleotides 1177-1257, Kikuchi, H. et al . , 1989; GenBank accession X16073) attached to the T7 RNA polymerase promoter sequence can be synthesized and - * -P labeled RNA transcripts (81 nucleotides in length) , corresponding to a portion of human tyrosinase mRNA may be generated.
  • Labeled ribozyme TYRRZ1 (sequence composition 5'- AAG-GCC-ACC-UGA-UGA-GUC-CGU-GA3-GAC-GAA-AUC-CCG-G-3 ' , see Table I) , designed to cleave after nucleotide 1222, can also be prepared using a synthetic deoxyoligonucleotide template (5' CCG- GGA-TTT-CGT-CCT-CAC-GGA-CTC-ATC-AGG-TGG-CCT-TC-TAT-AGT-GAG-TCG- TAT-TA 3') and a short synthetic deoxyoligonucleotide-"18mer" (5' TAA-TAC-GAC-TCA-CTA-TAG 3 ' ) , according to the methods of Example 1.
  • a synthetic deoxyoligonucleotide template 5' CCG- GGA-TTT-CGT-CCT-CAC-GGA-CTC-
  • the TYRRZl ribozyme and the tyrosinase RNA substrate can be mixed in a 1:2 molar ratio, and incubated at 37 : C for 90 minutes.
  • ribozyme and target substrate are incubated in the presence of 3OmM Mg " , two cleavage products of the expected sizes of 35nts and 46nts shoulci be produced.
  • the TYRRZl ribozyme composition may be used to cleave tyrosinase mRNA both in vi tro and in vivo .
  • a therapeutically effective amount of this ribozyme composition (lOng to lmg) can be incorporated into a formulation consisting of a delivery vehicle or carrier such as cationic liposomes. This formulation may be applied directly to an affected area of the skin.
  • the ribozyme composition contained in this formulation may be used to cleave the tyrosinase mRNA present m skin cells and thus it may modify the expression of the target protein and may thereby mitigate the cutaneous condition.
  • Example 17 Ribozvme cleavage of a short sequence corresponding to a portion of the glutathione reductase mRNA, a target in the alteration of pigmentation.
  • a fragment of human glutathione reductase antisense DNA (nucleotides 245-325, Tutic, M. et al . , 1990; GenBank accession #X15722) attached to the T7 RNA polymerase promoter sequence can be synthesized and P labeled RNA transcripts (81 nucleotides in length) , corresponding to ⁇ portion of human glutathione reductase mRNA may be generated.
  • Labeled ribozyme GRRZ1 (sequence composition 5 ' -ACA-CAU-CCC-UGA-UGA-GUC-CGU-GAG-GAC-GAA-AAU-UCA-C- 3', see Table I), designed to cleave after nucleotide 290, can also be prepared using a synthetic deoxyoligonucleotide template (5 ' GTG-AAT-TTT-CGT-CCT-CAC-GGA-CTC-ATC-AGG-GAT-GTG-TC-TAT-AGT- GAG-TCG-TAT-TA 3') and a short synthetic deoxyoligonucleotide- "18mer" (5' TAA-TAC-GAC-TCA-CTA-TAG 3') , according to the methods of Example 1.
  • a synthetic deoxyoligonucleotide template (5 ' GTG-AAT-TTT-CGT-CCT-CAC-GGA-CTC-A
  • the GRRZ1 ribozyme and the glutathione reductase RNA substrate can be mixed in a 1:2 molar ratio, and incubated at 37 C ro: 90 minutes, ⁇ ' hen ribozyme and target substrate are incubated in the presence of 30mM Mg", two cleavage products of the expected sizes of 35nts and 46nts should be produced.
  • the GRRZ1 ribozyme composition may be used to cleave glutathione reductase mRNA both m vi tro and m vi vo .
  • a therapeutically effective amount or this ribozyme composition (lOng to 1 mg) can be incorporated into a formulation consisting of a delivery vehicle or carri-ri such as cationic liposomes. This formulation may be applied directly to an afrected area of the skin.
  • the ribozyme composition contained m this formulation may be used to cleave the glutathione reductase mRNA present m skin
  • ⁇ 8 cells may modify the expression of the target protein and may thereby mitigate the cutaneous condition.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention a pour objet des procédés de production de compositions d'acide nucléique pour le traitement d'affections de la peau et des structures apparentées. Les molécules d'acide nucléique, telles que des ribozymes, qui interagissent spécifiquement avec l'expression de molécules biologiques cutanées et en modifient l'expression, peuvent être développées pour produire des réactifs thérapeutiques et cosmétiques efficaces et sans danger. Ces ribozymes peuvent être utilisés pour le traitement de troubles comprenant : le vieillissement, les agressions par l'environnement, les inflammations et la prédisposition génétique. Les procédés utilisés pour mettre au point ces réactifs sont décrits.
PCT/US1994/010617 1993-09-17 1994-09-16 Compositions a base de ribozymes pour la modification des phenotypes cutanes associes au vieillissement de la peau et des cheveux et a d'autres de leurs etats WO1995007924A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12235893A 1993-09-17 1993-09-17
US08/122,358 1993-09-17

Publications (1)

Publication Number Publication Date
WO1995007924A1 true WO1995007924A1 (fr) 1995-03-23

Family

ID=22402229

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/010617 WO1995007924A1 (fr) 1993-09-17 1994-09-16 Compositions a base de ribozymes pour la modification des phenotypes cutanes associes au vieillissement de la peau et des cheveux et a d'autres de leurs etats

Country Status (1)

Country Link
WO (1) WO1995007924A1 (fr)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0800398A4 (fr) * 1994-07-15 1999-10-20 Hope City CLIVAGE DE L'ARNM DE LA 5-g(a)-REDUCTASE
EP0943311A3 (fr) * 1998-01-14 2000-05-17 Kao Corporation Méthode por inhiber la croissance du poil
EP1005333A4 (fr) * 1997-02-25 2001-03-14 Univ Michigan Procedes et compositions servant a prevenir et a traiter un viellissement de la peau humaine du a l'age
FR2804960A1 (fr) * 2000-02-11 2001-08-17 Lvmh Rech Nouveaux oligonucleotides et utilisation d'oligonucleotides modulant l'expression de la tyrosinase et de la tyrosinase- related-protein 1 comme agents depigmentants
WO2001079504A1 (fr) * 2000-04-13 2001-10-25 Millennium Pharmaceuticals, Inc. 23155, nouvelle proteine humaine 5-$g(a) reductases et ses utilisations
WO2001030362A3 (fr) * 1999-10-26 2002-01-17 Immusol Inc Therapie ribozymique destinee au traitement de maladies proliferantes de la peau et des yeux
US6375948B1 (en) 1999-07-12 2002-04-23 Kao Corporation Treating method for suppressing hair growth
WO2003017917A3 (fr) * 2001-08-23 2003-11-13 Christos C Zouboulis Utilisation de substances non virales, obtenues par des techniques de biologie moleculaire, pour le traitement de l'acne
WO2004046354A1 (fr) * 2002-11-20 2004-06-03 Beiersdorf Ag Oligoribonucleotides pour le traitement de maladies degeneratives de la peau par l'intermediaire de l'interference arn
WO2005042031A3 (fr) * 2003-11-03 2005-09-09 Beiersdorf Ag Oligoribonucleotides servant a traiter une pigmentation indesirable de la peau et des poils/cheveux par interference arn

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
EMBO JOURNAL, Vol. 11, No. 12, issued 1992, HUILLIER et al., "Cytoplasmic Delivery of Ribozymes Leads to Efficient Reduction in alpha-lactalbumin mRNA Levels in C1271 Mouse Cells", pages 4411-4418. *
EMBO JOURNAL, Vol. 11, No. 4, issued 1992, STEINECKE et al., "Expression of a Chimeric Ribozyme Gene Results in Endonucleolytic Cleavage of Target mRNA and a Concomitant Reduction of Gene Expression in Vivo", pages 1525-1530. *
JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 261, No. 14, issued 15 May 1986, GOLDBERG et al., "Human Fibroblast Collagenase: Complete Primary Structure and Homology to an Oncogene Transformation-Induced Rat Protein", pages 6600-6605. *
JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 265, No. 28, issued 05 October 1990, SAXENA et al., "Ribozymes Correctly Cleave a Model Substrate and Endogenous RNA in Vitro", pages 17106-17109. *
JOURNAL OF MOLECULAR BIOLOGY, Vol. 223, issued 1992, SIUOD et al., "Preformed Ribozyme Destroys Tumor Necrosis Factor mRNA in Human Cells", pages 831-835. *
PROC. NATL. ACAD. SCI. U.S.A., Vol. 90, issued July 1993, YU et al., "A Hairpin Ribozyme Inhibits Expression of Diverse Strains of Human Immunodeficiency Virus Type 1", pages 6340-6344. *

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0800398A4 (fr) * 1994-07-15 1999-10-20 Hope City CLIVAGE DE L'ARNM DE LA 5-g(a)-REDUCTASE
EP1005333A4 (fr) * 1997-02-25 2001-03-14 Univ Michigan Procedes et compositions servant a prevenir et a traiter un viellissement de la peau humaine du a l'age
US7041658B2 (en) 1998-01-14 2006-05-09 Kao Corporation Method of inhibiting hair growth
EP0943311A3 (fr) * 1998-01-14 2000-05-17 Kao Corporation Méthode por inhiber la croissance du poil
US6747017B2 (en) 1998-01-14 2004-06-08 Kao Corporation Method of inhibiting hair growth
US6375948B1 (en) 1999-07-12 2002-04-23 Kao Corporation Treating method for suppressing hair growth
US7211278B2 (en) 1999-07-12 2007-05-01 Kao Corporation Treating method for suppressing hair growth
US7056499B2 (en) 1999-07-12 2006-06-06 Kao Corporation Treating method for suppressing hair growth
WO2001030362A3 (fr) * 1999-10-26 2002-01-17 Immusol Inc Therapie ribozymique destinee au traitement de maladies proliferantes de la peau et des yeux
FR2804960A1 (fr) * 2000-02-11 2001-08-17 Lvmh Rech Nouveaux oligonucleotides et utilisation d'oligonucleotides modulant l'expression de la tyrosinase et de la tyrosinase- related-protein 1 comme agents depigmentants
WO2001058918A3 (fr) * 2000-02-11 2002-03-14 Lvmh Rech Oligonucleotides modulant l'expression d'enzymes intervenant dansla synthese de pigments melaniques
WO2001079504A1 (fr) * 2000-04-13 2001-10-25 Millennium Pharmaceuticals, Inc. 23155, nouvelle proteine humaine 5-$g(a) reductases et ses utilisations
WO2003017917A3 (fr) * 2001-08-23 2003-11-13 Christos C Zouboulis Utilisation de substances non virales, obtenues par des techniques de biologie moleculaire, pour le traitement de l'acne
EP1925665A1 (fr) * 2001-08-23 2008-05-28 RiNA Netzwerk RNA-Technologien GmbH Utilisation d'agents actifs non viraux biologiques moléculaires destinés au traitement de l'acné
WO2004046354A1 (fr) * 2002-11-20 2004-06-03 Beiersdorf Ag Oligoribonucleotides pour le traitement de maladies degeneratives de la peau par l'intermediaire de l'interference arn
WO2005042031A3 (fr) * 2003-11-03 2005-09-09 Beiersdorf Ag Oligoribonucleotides servant a traiter une pigmentation indesirable de la peau et des poils/cheveux par interference arn

Similar Documents

Publication Publication Date Title
US5580547A (en) Stimulation of tanning by DNA fragments or single-stranded DNA
JP4056743B2 (ja) 新規オリゴヌクレオチド、および脱色剤として、メラニン色素合成に含まれる酵素の発現を調節するオリゴヌクレオチドの使用
US8946402B2 (en) Inhibition of hairless protein mRNA
US5955059A (en) Use of locally applied DNA fragments
CN102014859B (zh) 抑制黑素生成的新组合物及其应用
JP2009518022A (ja) 抗ミオシンＶａｓｉＲＮＡおよび皮膚の脱色
KR101938548B1 (ko) 마이크로 ｒｎａ를 포함하는 색소형성유전자 발현조절용 조성물
WO1995007924A1 (fr) Compositions a base de ribozymes pour la modification des phenotypes cutanes associes au vieillissement de la peau et des cheveux et a d'autres de leurs etats
US20060270621A1 (en) Inhibition of hair growth with RNAi targeting desmoglein 4 and nude mRNAs
JP2011254826A (ja) 皮膚脱色素剤としての、プロテイン−キナーゼｃベータ−１アイソフォームの発現を調節するヌクレオチド及びその使用
JP5208740B2 (ja) 脱色素剤としての新規チロシナーゼ特異性アンチジーンオリゴヌクレオチド
KR101849102B1 (ko) 마이크로 ｒｎａ를 포함하는 색소형성유전자 발현조절용 조성물
US20140336371A1 (en) Sirna molecule for inhibiting growth of melanin and application thereof
JP5599615B2 (ja) チロシナーゼ関連タンパク質−１（ｔｒｐ−１）をコードする遺伝子と相互作用してその発現を調節する新規オリゴヌクレオチド、および該オリゴヌクレオチドの脱色素剤としての使用
US7078390B1 (en) Ribozymes to growth factor originating in human platelet
US20050053580A1 (en) Use of microbiology non-viral substances for treating acne
KR101871920B1 (ko) 마이크로 ｒｎａ를 포함하는 조성물
Rosen et al. Interaction of TPA and ultraviolet B radiation in regulation of ODC gene expression in rat keratinocytes
KR20130000039A (ko) 마이크로 ｒｎａ를 포함하는 색소형성유전자 발현조절용 조성물
WO2008035291A2 (fr) Oligonucléotide d'arn double brin : composition pharmaceutique ou cosmétique le contenant et son utilisation en tant qu'ingrédient pharmaceutique actif dans le traitement des maladies associées aux androgènes
Park et al. A tyrosinase mimetic peptide inhibits tyrosinase activity in cultured human melanocytes
Kishimoto et al. Human vascular endothelial growth factor (VEGF) promoter-driven green fluorescent protein expression in transgenic mouse skin
Huh et al. Cloning of a putative keratin-associated protein cDNA expressed in various mouse tissues other than hair follicles
Lee et al. Repression of transglutaminase 3 gene expression by a single-stranded DNA binding protein
Thai et al. Characterization of the regulatory and minoxidil-responsive elements in the 5′ flanking region of the lysyl hydroxylase gene

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载